Tomoya Yokota

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Barbara Burtness, Kevin J. Harrington, Richard Greil et al. · The Lancet · 2019 · 3K citations · Full text

Neoadjuvant Therapy, Chemotherapy Versus Cetuximab, Medicine +7

BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer

Tomoya Yokota, Takashi Ura, Norio Shibata et al. · British Journal of Cancer · 2011 · 411 citations · Full text

Regulation of Bcl-2 expression by oncogenic Ras protein in hematopoietic cells.

Taisei Kinoshita, Tomoya Yokota, Katsumitsu Arai et al. · PubMed · 1995 · 152 citations

Sesamin, a lignan of sesame, down‐regulates cyclin D1 protein expression in human tumor cells

Tomoya Yokota, Y. Matsuzaki, Makoto Koyama et al. · Cancer Science · 2007 · 149 citations · Full text

A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigator’s choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of Asian patients versus the global population in checkmate 141

Naomi Kiyota, Yasuhisa Hasegawa, Shunji Takahashi et al. · Oral Oncology · 2017 · 138 citations · Full text